WALD Waldencast plc
USTechnologyAs of 2026-07-10 16:00
Why WALD matters now
Waldencast plc (WALD) is a US stock in Technology. The latest InvestLog snapshot shows $1.73 with +0.58% on the session and $204.6M in market capitalization; recent performance reads 1-month +26.72% and YTD -11.70%.
The latest financial table shown here is Q4 2025, with revenue of $139.8M, net income of $-60.3M, and EPS of $-0.51. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -8.3%.
The latest indexable market news headline is "Obagi Medical Announces FDA Approval of Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid Gel" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $2.50; recent insider activity includes Brookie Kelly filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.42
P/S
0.72
EV/EBITDA
-2.05
DCF Value
$-8.43
FCF Yield
-8.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
45.5%
Operating Margin
-22.7%
Net Margin
-84.4%
ROE
-47.8%
ROA
-28.1%
ROIC
-7.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $139.8M | $-60.3M | $-0.51 |
| FY 2025 | $272.1M | $-229.7M | $-2.01 |
| Q2 2025 | $132.3M | $-169.4M | $-1.51 |
| Q4 2024 | $142.3M | $-32.4M | $-0.29 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$2.50
Target (Median)
$2.50
Target Range
$2.00 - $3.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Technology
Industry
Software - Application
Country
US
Exchange
—
Beta
0.09
Waldencast plc operates as a specialized skincare enterprise, delivering sophisticated treatments aimed at improving various dermatological conditions. Its product offerings are crafted to minimize the visual impact of early aging, skin damage, uneven pigmentation, acne, and harm from sun exposure. These solutions are predominantly distributed through professional avenues such as dermatologists, plastic surgeons, medical spas, and other skincare professionals. The company's portfolio encompasses Obagi Medical, which provides groundbreaking skincare products designed to alleviate signs of skin aging, treat issues like dark spots, hyperpigmentation, and fine lines, while simultaneously protecting and enhancing skin's overall tone and texture. Additionally, its Obagi Clinical line features products specifically developed to stave off the initial indicators of skin aging. Founded in 1988, Waldencast plc is based in White Plains, New York.